Retinoic acid (RA), a potent inducer of cell differentiation, and N-(4-hydroxyphenyl)retinamide (4-HPR, fenretinide), a potent inducer of apoptosis, are well known as anticancer agents that are administered orally to patients for leukemia, breast and prostate cancer, respectively. However, it has not been studied whether both retinoids are effective on metastatic cancer. In mice implanted with M5076 cells, murine reticulum cell sarcoma survival times were prolonged by i.v. treatment of RA and 4-HPR entrapped in liposomes containing soybean-derived sterylglucoside mixture (SG), which accumulates in liver. In contrast, free RA and 4-HPR were inactive. These results indicate that RA and 4-HPR in SG-liposomes exhibit anticancer efficacy on metastatic cancers, and may have great potential for clinical use in the treatment of various cancers.
Retinoic acid (RA) induces terminal differentiation of the human acute myeloid leukemia cell line HL60 to cells having many of the functional and morphologic characteristics of mature granulocytes. 1) RA induces the differentiation of cells from acute promyelocytic leukemia patients in vitro 2) and, as a sole agent, it induces complete remission of patients with acute promyelocytic leukemia in vivo. [3] [4] [5] A high percentage of patients in complete remission relapse within a few months, [4] [5] [6] being resistant to further treatment with RA. 6, 7) N-(4-Hydroxyphenyl)retinamide (4-HPR, fenretinide), a synthetic amide of RA ( Fig. 1) alone is a poor inducer of differentiation of HL60 cells as compared to RA. 8) It induces apoptosis in HL60 and NB4 human leukemia cell lines, 9) as well as C33A, a human cervical carcinoma cell line, 10) and neuroblastoma.
11) 4-HPR is an effective chemopreventive 12) and antiproliferative agent 13, 14) used against a wide variety of tumor types, including breast, prostate, ovary, and bladder cancers. 4-HPR currently is in clinical trial for treatment of breast, 15) bladder, 14) and neuroblastoma 16) malignancies. In clinical trial, 4-HPR treatment showed side effects, decreasing serum retinol levels and causing night blindness. 17) Previous studies have shown the metastatic properties of the murine reticulum sarcoma cell line M5076. When these tumor cells were implanted by i.v. injection, metastasis occurred preferentially to liver, ovary, spleen, and kidney. 18) Recently, it has been shown that liposomes having glucose residues (SG-liposome) accumulated in liver and in spleen to the extent of approximately 40 and 8% total liposomes respectively at 2 h after i.v. injection. These have been useful as an effective liver targeting drug delivery system. 19) In order to evaluate effects on metastatic cancer, we administered RA and 4-HPR encapsulated in SG-liposomes with the intent of sustaining release and targeting the liver. In the present study, we found that RA and 4-HPR entrapped in SG-liposomes, prolonged the survival of mice implanted with M5076 cells and exhibited antitumor efficacy against this metastatic cancer.
MATERIALS AND METHODS
Chemicals and Cells RA and cholesterol (Ch) were obtained from Sigma Chemical Co. (St. Louis, MO, U.S.A.), 4-HPR was provided by Dr. R. C. Moon, University of Illinois, Chicago, IL, U.S.A. Dipalmitoylphosphatidylcholine (DPPC) was purchased from NOF (Tokyo, Japan). A soybean-derived sterylglucoside mixture (SG) containing b-sitosterol 3-b-Dglucoside, campesterol, stigmasterol, and brassicasterol was provided by Ryukakusan Co. (Tokyo, Japan). All other chemicals were of reagent grade. Murine reticulosarcoma (M5076) was obtained from Dr. T. Yamori of the Cancer Chemotherapy Center, Japan Foundation for Cancer Research (Tokyo, Japan).
Cells Murine reticulosarcoma cell line (M5076) was grown in RPMI 1640 medium (GIBCO, Grand Island, NY, U.S.A.) supplemented with 10 mM 4-(2-hydroxyethyl)-1-piperazinethanesulfonic acid (HEPES), pH 7.3 and 15% fetal bovine serum (FBS) as described previously. 20) Human hepatoma cell line, HepG2 was obtained from RIKEN cell bank (Tokyo, Japan). HepG2 cells were grown in RPMI 1640 medium containing 10% FBS and subcultured every week. Attached cells were removed from the tissue culture flask surface with trypsin-EDTA (GIBCO).
Cells were incubated at 37°C in a humidified atmosphere of 5% CO 2 in air. Cell numbers were estimated using on an electric particle counter (Coulter Electronics, Hialeah, FL) and viability was determined by trypan blue dye exclusion.
Cell Growth M5076 cells (2ϫ10 5 /ml) were grown in RPMI 1640 medium containing 15% FBS and various concentrations of retinoids. M5076 cells were harvested by trypsinizing to dislodge cells into medium. Cell number and viability were measured. The percentage of net growth is shown with values adjusted by subtracting the initial cell concentration (cells/ml) of experimental cultures from the initial concentrations of control cultures which were defined as 100% (Fig. 3) . Values for percent net growth were calculated with the following formula: [(cell concentration of experimental culture)Ϫ(initial cell concentration)/(cell concentration of control culture)Ϫ(initial cell concentration)]ϫ100. Preparation of Liposome-Entrapped Retinoids Liposome-entrapped retinoids were prepared from 60 mmol DPPC, 10 mmol SG, 30 mmol Ch and 3 mmol retinoid (DPPC : SG : Ch : retinoidϭ6 : 1 : 3 : 0.3 molar ratio) according to the reverse-phase evaporation method described previously. 19, 21) Liposomes were extruded through a polycarbonate membrane (Nuclepore, U.S.A.) with a pore size of 200 nm at 50-60°C. Entrapped retinoids were separated from free retinoids through a Sephadex G-50 column (Pharmacia, Sweden) with the 1/10 diluted phosphate-buffered saline. Aliquots of liposomes were analyzed for the measurement of retinoids as described below. The particle size distribution of liposome was determined using a dynamic laser light scattering instrument (Model ELS-800, Ostuka Electronics Co., Ltd., Osaka) and lipid concentration of liposomes were determined using a Wako phospholipid B test (Wako Pure Chemical Ind., Ltd., Osaka). Liposomes were stored at 4°C in the absence of light.
Quantitation of Retinoids by High Pressure Liquid Chromatography (HPLC) HepG2 cells (2ϫ10 6 cells/ml) were incubated at 37°C for 0-1 h with free or SG-liposome entrapped retinoids at the concentration of 360 nM. Retinoids in mixtures were extracted with equivalent volumes of ethyl acetoacetate containing 1% acetic acid under argon gas. Mixtures were centrifuged at 10000ϫg for 5 min, then retinoids in organic layers were analyzed by HPLC using a LC-10As pump, SIL-10A injector, and RF-10AXL detector (Shimadzu Co., Kyoto, Japan). A ZORBAX ODS (C 18 reverse-phase column, 4.6 mm IDϫ25 cm, 5 mm, HEWLETT PACKARD, Palo Alto, CA, U.S.A.) was used to separate RA and 4-HPR. The column was eluted with 10 mM NH 4 OAc in a methanol/water gradient (30-70% (0-10 min), 70-90% (10-32 min), 90-100% (32-36 min) and then, 100% (36-40 min)) at a flow rate of 1.5 ml/min with UV monitoring at wave lengths of maximum absorbance for each retinoid; 340 nm for RA and 4-HPR. Elution time was 26 min for RA and 31 min for 4-HPR. Measurements were made using authentic RA and 4-HPR as internal standards.
Animals and Tumor Models Specific-pathogen-free female C57BL/6 mice (19-20 g, 7 weeks old) were purchased from Tokyo Laboratory Animal Science Company Co. Ltd. (Tokyo, Japan). M5076 cells were kept in vivo as subcutaneous solid tumors in C57BL/6 mice by transplantation every two weeks into the right axillary subcutaneous tissue. To obtain a suspension of tumor cells for transplantation, M5076 cells were prepared, homogenized and suspended in 3 ml of sterile saline per gram of subcutaneous solid tumor (3ϫ10 6 cells/ml). This tumor cell suspension was injected intravenously in mice as described below.
Evaluation of Antitumor Activity ln therapeutic experiments of liver metastatic cancer, a group of nine C57BL/6 mice were inoculated intravenously on day 0 with M5076 cells (6ϫ10 5 cells, 0.2 ml) per mouse. On Day 8 after implantation of tumor cells, mice were given as single i.v. doses of free or liposomal retinoids (0.585 mg/kg for RA; 0.762 mg/kg for 4-HPR). The control group was given sterile saline instead of retinoid on Day 8. Mice were weighed everyday. Survival times were recorded in days following tumor administration. Antitumor activity was evaluated by comparing mean survival times of treated animals (T) with those of controls (C), and by calculation of increased life-span (ILS), (T/CϪ1)ϫ100 (%).
Statistical Analysis The statistical significance of the results was assessed by the nonparametric test of Kruskal-Wallis and Student's t-test for the survival experiment.
RESULTS
Characterization of SG-Liposome Entrapping of RA and 4-HPR Characterization of SG-liposome entrapping of RA and 4-HPR (Fig. 1) is summarized in Table 1 . Properties of SG-liposome containing RA and 4-HPR did not differ significantly, e.g. drug and lipid concentrations, drug/lipid (drug and lipid ratio), and size, even though their structures were distinct (Fig. 1) .
Survival Times of M5076 Bearing-Mice Treated with RA and 4-HPR Previous studies have shown that with the exception of metastatic cancer RA and 4-HPR exhibit potent anticancer activities against various cancers, in vitro and in vivo. 8, 10, 11, [22] [23] [24] These results led us to investigate the antitumor efficacy of these retinoids entrapped in SG-liposome in a liver metastatic cancer model with M5076 cells in vivo.
M5076 cells were injected into mice via tail vein on Day 0. On Day 8 retinoids encapsulated in liposomes and liposomes without retinoid as control were administrated by i.v. Body weights of mice in all groups did not change noticeably. Liver, heart, lung, kidney, and spleen of mice 14 d after i.v. injection of M5076 cells were approximately two-fold larger than those in normal mice. 23) Livers of M5076 bearing mice exhibited white spots, which were identified as liver tumors. centration of 50 mM were prolonged and survival lines were shifted to the right in Fig. 2 . The mean survival times of RA and 4-HPR were 16.9 and 18.9 d, respectively, as compared with that of control, 14.5 d ( Table 2 ). The differences between control and retinoids were significant (pϽ0.01 for RA and pϽ0.001 for 4-HPR). Free RA and 4-HPR did not prolong survival times (data not shown). These results indicated that the retinoids encapsuled in SG-liposomes showed great antitumor activity. Percentage increase in life spans (ILS) are 16.8% for RA and 30.1% for 4-HPR (Table 1) . 4-HPR exhibited more potent antitumor efficacy than RA.
Effects of Retinoids on Growth of M5076 Cells
Murine reticulosarcoma M5076 cells, were grown in culture containing various concentrations of retinoids and 15% FBS, which was required for exponential cell growth. 4-HPR at a concentration of 10 mM inhibited M5076 cell growth to the extent of approximately 40% (Fig. 3) . In contrast, cell growth was not inhibited by 1 mM or 10 mM RA or 1 mM 4-HPR (Fig.  3) . These results indicate that growth of M5076 cells was suppressed by a high concentration of 4-HPR, but not by RA.
Stability of Free and SG-Liposome-Entrapped Retinoids in the Presence of HepG2 Cells
Free and SGliposome-entrapped retinoids were incubated at 37°C with HepG2 cells, and then remaining retinoids were extracted and quantified by HPLC. Retention times were 26 min for RA and 31 min for 4-HPR. After incubation of free RA with HepG2 cells, the concentration of RA decreased markedly to 90% at 30 min and to 32% at 1 h as compared with the initial RA concentration, which was defined as 100% (Fig. 4A) . On the other hand, the concentration of 4-HPR decreased to 93% after 30 min and to 87% after 1 h incubation (Fig. 4B) . However, the levels of RA and 4-HPR in SG-liposomes did not change during the incubation (Fig. 4A, B) . These results indicate that free RA and free 4-HPR may be more unstable in the presence of HepG2 cells as compared with SG-liposomeentrapped RA and 4-HPR, and that SG-liposome preparation may protect retinoids against metabolizing enzymes. This may facilitate sustained release, thereby maintaining high concentrations of these retinoids.
DISCUSSION
The current study shows that SG-liposomes containing RA or 4-HPR (Fig. 1) could be prepared in a stable form that prevented their metabolism (Fig. 4) . Survival times of mice implanted with M5076 metastatic cancer, following administration of RA or 4-HPR entrapped in SG-liposomes, were prolonged as compared with control mice (Fig. 2, Table 2 ). In contrast, free RA and 4-HPR were inactive. In addition, while RA did not inhibit M5076 cell growth, 4-HPR at a concentration of 10 mM was inhibitory (Fig. 3) . These results indicated that SG-liposomal RA or 4-HPR may have potential for clinical use in the treatment of various cancers.
One reason for using liposomes was to enhance solubility of RA and 4-HPR, which are highly hydrophobic. Additional reason was to extend blood residence time in order to allow optimal delivery to target tissues. The intent was to stabilize components in liposomes so as to prolong circulation time in blood. 25) Previous studies of drug tumor targeting have shown that liposomes consisting of the ganglioside GM1 26) or amphipathic poly(ethylene glycol) 26, 27) prevent drug uptake into the reticuloendothelial system. Additionally, liposomes carrying galactose residues tend to target hepatocyte, 28) while liposomes having glucose residues (DPPC : SG : Chϭ6 : 1 : 3, molar ratio) accumulate in the liver following i.v. administration, thereby making these useful for effec- tive liver targeting. 19) On the other hand, M5076 murine reticulum cell sarcoma preferentially metastasizes to liver, ovary, spleen, and kidney regardless of method of tumor injection. 18) In the current study, RA and 4-HPR encapsulated in liposomes containing SG, prolonged survival of M5076 cell-implanted mice (Fig. 2, Table 2 ). This is the first report that RA and 4-HPR entrapped in SG-liposomes exhibit antitumor efficacy in an animal M5076 tumor metastasis model.
RA and 4-HPR are well known clinical anti-cancer agents that are administrated orally to leukemia patients in a capsule form. In the case of RA, an inducer of cell differentiation, patients with acute promyelocytic leukemia (APL) initially respond to RA-therapy with complete remission. [3] [4] [5] However, frequently relapses occur in association with leukemia cells that are resistant to differentiation by RA. [4] [5] [6] [7] On the other hand, treatment with 4-HPR, an inducer of cell apoptosis, shows side effects, including decreased serum retinol levels that can result in night blindness. 17) Thus, oral administration with high doses of retinoids may result in side effects that temper their values as potent anti-cancer drugs. Regardless of the reason (or reasons) for relapse and side effects, one approach toward ameliorating these problems is to modify the drug delivery system so as to target tissues and lower plasma levels of RA and 4-HPR needed for clinical effects. SG-liposomes may carry RA and 4-HPR to target organs and provide sustained release. In the present study, it was found that RA and 4-HPR entrapped in SG-liposomes exhibit antitumor efficacy against metastatic cancer in vivo. It would be interesting to examine whether this new drug delivery system would eliminate clinical problems as described above.
We have studied the antitumor activities of RA and 4-HPR (Fig. 1) by measuring their ability to suppress cell growth in vitro using a variety of cell lines. These include HL60 leukemia cells; HL60R cells which are a subclone of HL60 cells that are resistant to RA; MCF-7 breast cancer cells, that have estradiol receptors (ER-positive); MCF-7/Adr R cells which are a subclone of MCF-7 cells that are resistant to RA (ER-negative); HepG2 hepatoma cells and DU-145 prostate cancer cells. 8, 10, 11, [22] [23] [24] RA inhibited cell growth of HL60 and MCF-7 cells with high efficacy. 4-HPR suppressed growth of various human cancer cells (all described above) with a broad spectrum and high efficacy, even against cells that were resistant to RA (e.g. HL60R and MCF-7/Adr R cells). Also, RA and 4-HPR were effective against M5076-implanted mice in vivo, which represents a metastatic cancer model (Fig. 2, Table 2 ). However, in assays measuring growth suppression of M5076 cells, while 4-HPR was active at a concentration of 10 mM, RA was inactive (Fig. 3) . It is possible that both RA and 4-HPR may affect metastasis or growth of metastatic cells. Further studies are needed to ascertain which processes or steps are affected, e.g. cell growth of M5076 (primary neoplasm), metastasis, or cell growth of metastatic cancer etc.
RA and 4-HPR are effective anticancer drugs in M5076 tumor models. The results reported herein suggest potential clinical anticancer applications of RA and 4-HPR encapsuled in SG-liposomes. Studies are presently underway to measure the effectiveness of RA and 4-HPR encapsuled in SG-liposome against other animal tumor models.
